QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:COLL

Collegium Pharmaceutical - COLL Stock Forecast, Price & News

$28.08
+0.70 (+2.56%)
(As of 01/31/2023 05:19 PM ET)
Add
Compare
Today's Range
$27.09
$28.40
50-Day Range
$21.25
$28.74
52-Week Range
$14.04
$30.22
Volume
278,604 shs
Average Volume
467,745 shs
Market Capitalization
$942.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
17.2% Upside
$33.00 Price Target
Short Interest
Bearish
12.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
0.36mentions of Collegium Pharmaceutical in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$4.38 M Sold Last Quarter
Proj. Earnings Growth
54.12%
From $3.64 to $5.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

659th out of 1,055 stocks

Pharmaceutical Preparations Industry

337th out of 518 stocks


COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
COLL vs. ZTS: Which Stock Is the Better Value Option?
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Collegium Reports Third Quarter 2022 Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Collegium Pharmaceutical Q2 2022 Earnings Preview
Collegium Pharmaceutical Inc Stock Quote COLL
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.00
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+17.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$71.52 million
Pretax Margin
-16.57%

Debt

Sales & Book Value

Annual Sales
$361.68 million
Cash Flow
$2.24 per share
Book Value
$5.87 per share

Miscellaneous

Free Float
32,115,000
Market Cap
$942.70 million
Optionable
Optionable
Beta
0.82

Key Executives

  • Mr. Michael Thomas Heffernan B.S. PharmMr. Michael Thomas Heffernan B.S. Pharm (Age 59)
    R.Ph., Co-Founder & Chairman
    Comp: $110k
  • Mr. Joseph J. CiaffoniMr. Joseph J. Ciaffoni (Age 52)
    Pres, CEO & Director
    Comp: $1.1M
  • Ms. Colleen TupperMs. Colleen Tupper (Age 47)
    Exec. VP & CFO
    Comp: $631.24k
  • Ms. Shirley R. KuhlmannMs. Shirley R. Kuhlmann (Age 39)
    Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.
    Comp: $620.1k
  • Mr. Scott DreyerMr. Scott Dreyer (Age 50)
    Exec. VP & Chief Commercial Officer
    Comp: $591k
  • Dr. Richard Malamut M.D. (Age 63)
    Exec. VP & Chief Medical Officer
    Comp: $612.2k
  • Ms. Alex Dasalla
    Head of Investor Relations
  • Mr. Bart J. Dunn
    Exec. VP of Strategy & Corp. Devel.
  • Ms. Marlo Manning
    Head of HR
  • Mr. Scott Sudduth
    Head of Technical Operations













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2023?

4 equities research analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $26.00 to $42.00. On average, they predict the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2023?

Collegium Pharmaceutical's stock was trading at $23.20 at the start of the year. Since then, COLL stock has increased by 18.0% and is now trading at $27.38.
View the best growth stocks for 2023 here
.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a increase in short interest in January. As of January 15th, there was short interest totaling 3,970,000 shares, an increase of 8.5% from the December 31st total of 3,660,000 shares. Based on an average daily volume of 306,100 shares, the days-to-cover ratio is currently 13.0 days. Approximately 12.3% of the shares of the stock are sold short.
View Collegium Pharmaceutical's Short Interest
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings data on Thursday, November, 3rd. The specialty pharmaceutical company reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.08. The specialty pharmaceutical company earned $127.01 million during the quarter, compared to the consensus estimate of $123.65 million. Collegium Pharmaceutical had a negative net margin of 11.84% and a positive trailing twelve-month return on equity of 12.66%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2023 earnings guidance on Wednesday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $550.58 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.61%), Assenagon Asset Management S.A. (0.40%), Exchange Traded Concepts LLC (0.23%), Acorn Financial Advisory Services Inc. ADV (0.16%), Values First Advisors Inc. (0.14%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends
.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $27.38.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $919.15 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or ($1.26) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 152 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 1/31/2023 by MarketBeat.com Staff